Protara Therapeutics, Inc. stock is up 21.01% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November.
Protara Therapeutics, Inc. engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the. treatment of lymphatic malformations. It also develops intravenous choline chloride, an. investigational phospholipid substrate replacement therapy.